$EMED
Electromedical Technologies, Inc Stock $emed

$emed Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000141057822000752 Filed on March 31, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$236.8K	$907.4K	$180.5K
YoY Change	31.21%	22.96%	-78.25%
Cost Of Revenue	$41.17K	$199.2K	$54.49K
YoY Change	-24.44%	2.5%	-77.15%
Gross Profit	$195.6K	$708.1K	$126.0K
YoY Change	55.28%	30.27%	-78.69%
Gross Profit Margin	82.61%	78.04%	69.81%
Selling, General & Admin	$1.681M	$4.508M	-$95.00K
YoY Change	-1869.13%	21.51%	-104.36%
% of Gross Profit	859.06%	636.66%	-75.4%
Research & Development		$215.3K
YoY Change		581.39%
% of Gross Profit		30.41%
Depreciation & Amortization	$5.470K	$21.88K	$5.470K
YoY Change	0.0%	0.0%	-50.0%
% of Gross Profit	2.8%	3.09%	4.34%
Operating Expenses	$1.686M	$4.724M	-$57.93K
YoY Change	-3010.65%	26.24%	-102.56%
Operating Profit	-$1.491M	-$3.800M	$183.9K
YoY Change	-910.41%	20.01%	-111.02%
Interest Expense	-$354.9K	$3.314M	-$593.6K
YoY Change	-40.21%	330.6%	983.0%
% of Operating Profit			-322.74%
Other Income/Expense, Net	$0.00	-$4.680M	-$570.00
YoY Change	-100.0%	563.78%	-97.27%
Pretax Income	-$1.845M	-$8.480M	-$410.3K
YoY Change	349.83%	119.03%	-76.48%
Income Tax
% Of Pretax Income
Net Earnings	-$1.845M	-$8.480M	-$410.3K
YoY Change	349.83%	119.03%	-76.48%
Net Earnings / Revenue	-779.29%	-934.59%	-227.31%
Basic Earnings Per Share		-$0.24
Diluted Earnings Per Share	-$21.72K	-$0.24	-$14.35K
COMMON SHARES
Basic Shares Outstanding	87.73M	50.99M
Diluted Shares Outstanding		50.99M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$383.2K	$383.2K	$264.9K
YoY Change	44.64%	44.64%
Cash & Equivalents	$383.2K	$383.2K	$264.9K
Short-Term Investments
Other Short-Term Assets	$38.00K	$38.00K	$285.9K
YoY Change	-86.71%	-86.71%	334.24%
Inventory	$218.5K	$218.5K	$78.71K
Prepaid Expenses
Receivables	$35.09K	$35.09K	$17.69K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$674.8K	$674.8K	$647.2K
YoY Change	4.26%	4.26%	509.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$727.3K	$727.3K	$749.2K
YoY Change	-2.92%	-2.92%	-2.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$20.60K
YoY Change	-100.0%	-100.0%	-19.46%
Total Long-Term Assets	$727.3K	$727.3K	$769.8K
YoY Change	-5.52%	-5.52%	-3.37%
TOTAL ASSETS
Total Short-Term Assets	$674.8K	$674.8K	$647.2K
Total Long-Term Assets	$727.3K	$727.3K	$769.8K
Total Assets	$1.402M	$1.402M	$1.417M
YoY Change	-1.05%	-1.05%	56.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$214.8K	$226.1K	$262.6K
YoY Change	-18.21%	-21.04%	-6.93%
Accrued Expenses	$317.0K	$317.0K	$201.8K
YoY Change	57.1%	57.1%	-30.36%
Deferred Revenue	$0.00		$28.65K
YoY Change	-100.0%
Short-Term Debt	$0.00	$0.00	$39.50K
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$899.1K	$899.1K	$631.0K
YoY Change	42.48%	42.48%	-62.54%
Total Short-Term Liabilities	$1.442M	$1.442M	$2.019M
YoY Change	-28.58%	-28.58%	-12.08%
LONG-TERM LIABILITIES
Long-Term Debt	$673.3K	$673.3K	$700.9K
YoY Change	-3.93%	-3.93%	-10.08%
Other Long-Term Liabilities	$9.167K	$9.170K	$15.60K
YoY Change	-41.25%	-41.22%	37.96%
Total Long-Term Liabilities	$9.167K	$682.5K	$15.60K
YoY Change	-41.25%	-4.75%	-98.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.442M	$1.442M	$2.019M
Total Long-Term Liabilities	$9.167K	$682.5K	$15.60K
Total Liabilities	$2.125M	$2.125M	$2.736M
YoY Change	-22.33%	-22.33%	-11.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$21.88M		-$9.632M
YoY Change	127.19%
Common Stock	$876.00		$269.00
YoY Change	225.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$722.5K	-$722.5K	-$1.319M
YoY Change
Total Liabilities & Shareholders Equity	$1.402M	$1.402M	$1.417M
YoY Change	-1.05%	-1.05%	56.94%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$1.845M	-$8.480M	-$410.3K
YoY Change	349.83%	119.03%	-76.48%
Depreciation, Depletion And Amortization	$5.470K	$21.88K	$5.470K
YoY Change	0.0%	0.0%	-50.0%
Cash From Operating Activities	-$287.6K	-$1.194M	-$541.0K
YoY Change	-46.84%	-10.7%	3036.35%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	506.0K	1.312M	720.4K
YoY Change	-29.77%	-18.08%	4076.52%
NET CHANGE
Cash From Operating Activities	-287.6K	-1.194M	-541.0K
Cash From Investing Activities
Cash From Financing Activities	506.0K	1.312M	720.4K
Net Change In Cash	218.4K	118.3K	179.4K
YoY Change	21.7%	-55.36%
FREE CASH FLOW
Cash From Operating Activities	-$287.6K	-$1.194M	-$541.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50992414
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22300579
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001715819
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	000-56192
CY2021	dei	Entity Registrant Name EntityRegistrantName	ELECTROMEDICAL TECHNOLOGIES, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2619815
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	16561 N. 92nd Street
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ste. 101
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Scottsdale
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	AZ
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	85260
CY2021	dei	City Area Code CityAreaCode	888
CY2021	dei	Local Phone Number LocalPhoneNumber	880-7888
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Public Float EntityPublicFloat	4845413
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	87725842
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	104955567
CY2021	dei	Auditor Name AuditorName	dbbmckennon
CY2021	dei	Auditor Firm AuditorFirmId	3501
CY2021	dei	Auditor Location AuditorLocation	San Diego, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	383170
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	264913
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35085
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17694
CY2021Q4	us-gaap	Inventory Net InventoryNet	218510
CY2020Q4	us-gaap	Inventory Net InventoryNet	78712
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	38002
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	285860
CY2021Q4	us-gaap	Assets Current AssetsCurrent	674767
CY2020Q4	us-gaap	Assets Current AssetsCurrent	647179
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20601
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	727344
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	749219
CY2021Q4	us-gaap	Assets Assets	1402111
CY2020Q4	us-gaap	Assets Assets	1416999
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	214785
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	262614
CY2021Q4	elcq	Credit Cards Payable CreditCardsPayable	11283
CY2020Q4	elcq	Credit Cards Payable CreditCardsPayable	23710
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	317037
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	201814
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	28651
CY2021Q4	elcq	Discount On Convertible Promissory Notes Current DiscountOnConvertiblePromissoryNotesCurrent	723166
CY2020Q4	elcq	Discount On Convertible Promissory Notes Current DiscountOnConvertiblePromissoryNotesCurrent	1277255
CY2021Q4	elcq	Convertible Promissory Notes Payable Current ConvertiblePromissoryNotesPayableCurrent	811687
CY2020Q4	elcq	Convertible Promissory Notes Payable Current ConvertiblePromissoryNotesPayableCurrent	257398
CY2021Q4	elcq	Related Party Notes Payable Current RelatedPartyNotesPayableCurrent	57875
CY2020Q4	elcq	Related Party Notes Payable Current RelatedPartyNotesPayableCurrent	332500
CY2020Q4	elcq	Payroll Protection Program Loan PayrollProtectionProgramLoan	39500
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	12846
CY2021Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	29502
CY2020Q4	us-gaap	Loans Payable To Bank Current LoansPayableToBankCurrent	28260
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	831852
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1442169
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2019145
CY2021Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	518849
CY2020Q4	us-gaap	Long Term Loans From Bank LongTermLoansFromBank	546552
CY2021Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	154429
CY2020Q4	us-gaap	Other Loans Payable Long Term OtherLoansPayableLongTerm	154302
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9167
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15603
CY2021Q4	us-gaap	Liabilities Liabilities	2124614
CY2020Q4	us-gaap	Liabilities Liabilities	2735602
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87725842
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27175800
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	876
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	269
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20804333
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7957860
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21882712
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9631732
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-722503
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1318603
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1402111
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1416999
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	907362
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	737958
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	199234
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	194384
CY2021	us-gaap	Gross Profit GrossProfit	708128
CY2020	us-gaap	Gross Profit GrossProfit	543574
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4508391
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3710262
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-3800263
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-3166688
CY2021	us-gaap	Interest Expense InterestExpense	3313852
CY2020	us-gaap	Interest Expense InterestExpense	769591
CY2020	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-7784
CY2021	elcq	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	1415685
CY2020	elcq	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-71413
CY2021	elcq	Other Nonoperating Income Expenses OtherNonoperatingIncomeExpenses	-432
CY2020	elcq	Other Nonoperating Income Expenses OtherNonoperatingIncomeExpenses	926
CY2021	elcq	Debt Instrument Forgiveness Of Debt DebtInstrumentForgivenessOfDebt	-50083
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4679886
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-705036
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8480149
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-3871724
CY2021	elcq	Deemed Dividend Related To Warrant Resets DeemedDividendRelatedToWarrantResets	3770831
CY2020	elcq	Deemed Dividend Related To Warrant Resets DeemedDividendRelatedToWarrantResets	507307
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12250980
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4379031
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50992414
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22300579
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-2184437
CY2020	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	7352
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2163900
CY2020	elcq	Stock Issued During Period Value In Conjunction With Convertible Promissory Notes StockIssuedDuringPeriodValueInConjunctionWithConvertiblePromissoryNotes	42969
CY2020	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	37149
CY2020	elcq	Adjustments To Additional Paid In Capital Warrants Issued In Conjunction With Convertible Promissory Notes AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConjunctionWithConvertiblePromissoryNotes	238375
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	50000
CY2020	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	36433
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	118800
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21807
CY2020	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	641094
CY2020	elcq	Stock Issued During Period Value Conversion Of Convertible Securities Related Party StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesRelatedParty	1452545
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-3871724
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1318603
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	906226
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	57191
CY2021	elcq	Value Of Warrants Issued In Conjunction With Convertible Promissory Notes ValueOfWarrantsIssuedInConjunctionWithConvertiblePromissoryNotes	1095096
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5226074
CY2021	elcq	Stock Issued During Period Value Conversion Of Convertible Note And Notes Payable StockIssuedDuringPeriodValueConversionOfConvertibleNoteAndNotesPayable	124935
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1666727
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8480149
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-722503
CY2021	us-gaap	Profit Loss ProfitLoss	-8480149
CY2020	us-gaap	Profit Loss ProfitLoss	-3871724
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3765
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2630144
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2222856
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21875
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21875
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-4979
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-40529
CY2021	elcq	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	1415685
CY2021	elcq	Forgiveness Of Debt Instrument ForgivenessOfDebtInstrument	50083
CY2020	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-7784
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3036792
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	684901
CY2020	elcq	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-71413
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	2839
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17391
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5792
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	17401
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	139798
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	54018
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-285860
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	205029
CY2021	elcq	Increase Decrease In Credit Card Payables IncreaseDecreaseInCreditCardPayables	-12427
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	11452
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	383170
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1510000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	264913
CY2021	us-gaap	Interest Paid Net InterestPaidNet	154081
CY2020	us-gaap	Interest Paid Net InterestPaidNet	48660
CY2020	elcq	Inventory Deposits Converted To Related Party Notes Payable InventoryDepositsConvertedToRelatedPartyNotesPayable	15000
CY2020	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	155900
CY2021	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	26334
CY2020	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	18787
CY2021	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-158875
CY2020	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-500
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	7352
CY2021	elcq	Warrants Common Stock And Beneficial Conversion Feature Issued In Conjunction With Convertible Promissory Note WarrantsCommonStockAndBeneficialConversionFeatureIssuedInConjunctionWithConvertiblePromissoryNote	1095096
CY2020	elcq	Warrants Common Stock And Beneficial Conversion Feature Issued In Conjunction With Convertible Promissory Note WarrantsCommonStockAndBeneficialConversionFeatureIssuedInConjunctionWithConvertiblePromissoryNote	922438
CY2021	elcq	Derivative Liabilities Issued In Conjunction With Convertible Promissory Notes DerivativeLiabilitiesIssuedInConjunctionWithConvertiblePromissoryNotes	1197607
CY2020	elcq	Derivative Liabilities Issued In Conjunction With Convertible Promissory Notes DerivativeLiabilitiesIssuedInConjunctionWithConvertiblePromissoryNotes	903265
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5223235
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	118800
CY2020	elcq	Conversion Of Kiss Liability Related Party To Common Stock ConversionOfKissLiabilityRelatedPartyToCommonStock	1452545
CY2020	elcq	Increase Decrease In Credit Card Payables IncreaseDecreaseInCreditCardPayables	-7300
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	205982
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-71824
CY2021	elcq	Increase Decrease In Customer Deposits Operating Activities IncreaseDecreaseInCustomerDepositsOperatingActivities	-28651
CY2020	elcq	Increase Decrease In Customer Deposits Operating Activities IncreaseDecreaseInCustomerDepositsOperatingActivities	-11469
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-6436
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	4297
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1193688
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1336660
CY2020	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-40307
CY2020	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	39500
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1458200
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12846
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	6000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13567
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1311945
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1601573
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	118257
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	264913
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	264913
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	431766
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	379812
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of certain assets and liabilities, certain disclosures at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates affecting the financial statements have been prepared on the basis of the most current and best available information. However, actual results from the resolution of such estimates and assumptions may vary from those used in the preparation of the financial statements.</p>
CY2021	elcq	Accumulated Net Loss AccumulatedNetLoss	17600000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1193688
CY2021	elcq	Working Capital Deficit WorkingCapitalDeficit	767402
CY2020	elcq	Sales Returns Allowance SalesReturnsAllowance	6990
CY2021	elcq	Sales Returns Allowance SalesReturnsAllowance	6990
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	28651
CY2021	elcq	Initial Warranty Period InitialWarrantyPeriod	P3Y
CY2021Q4	us-gaap	Deferred Income DeferredIncome	28252
CY2020Q4	us-gaap	Deferred Income DeferredIncome	35200
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1000
CY2021Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	13900
CY2020Q4	us-gaap	Receivables From Customers ReceivablesFromCustomers	12100
CY2021Q4	us-gaap	Due From Customer Acceptances DueFromCustomerAcceptances	12800
CY2020Q4	us-gaap	Due From Customer Acceptances DueFromCustomerAcceptances	0
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	28651
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	831852
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1415685
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	1197607
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-3445144
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	831852
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	831852
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1444761
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-63629
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	903265
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	831852
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	547256
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	115490
CY2019Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	25580
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	60021
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	65000
CY2020Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	20061
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	880340
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	132945
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	747395
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	333084
CY2021	elcq	Increase Decrease In Operating Loss Carryforwards IncreaseDecreaseInOperatingLossCarryforwards	1339245
CY2020	elcq	Increase Decrease In Operating Loss Carryforwards IncreaseDecreaseInOperatingLossCarryforwards	1062772
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	39500
CY2020Q3	us-gaap	Share Price SharePrice	2.02
CY2020Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	2000000
CY2020Q2	elcq	Number Of Employees NumberOfEmployees	1
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3876152
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2536907
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	61000
CY2020Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	58000
CY2021	elcq	Standard Warranty Period StandardWarrantyPeriod	P3Y
CY2021Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	14828
CY2020Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	17483
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	215320
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31600
CY2021Q4	elcq	Stock Options Warrants And Convertible Promissory Notes With Underlying Shares StockOptionsWarrantsAndConvertiblePromissoryNotesWithUnderlyingShares	32883205
CY2020Q4	elcq	Stock Options Warrants And Convertible Promissory Notes With Underlying Shares StockOptionsWarrantsAndConvertiblePromissoryNotesWithUnderlyingShares	3803949
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	57875
CY2021	elcq	Interest Income Expense Related Party Net InterestIncomeExpenseRelatedPartyNet	18590
CY2020	elcq	Interest Income Expense Related Party Net InterestIncomeExpenseRelatedPartyNet	386
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1534853
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1534653
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	723166
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1277255
CY2021Q4	us-gaap	Notes Payable NotesPayable	811687
CY2020Q4	us-gaap	Notes Payable NotesPayable	257398
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1534853
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	723166
CY2021Q4	us-gaap	Notes Payable NotesPayable	811687
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1534653
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1277255
CY2020Q4	us-gaap	Notes Payable NotesPayable	257398
CY2020Q2	elcq	Fair Value Of Common Stock FairValueOfCommonStock	42969
CY2020Q2	elcq	Fair Value Of Warrants FairValueOfWarrants	48231
CY2020Q2	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	8800
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	899987
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	899987
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	172643
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	150768
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	727344
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	749219
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21875
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21875
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	158875
CY2020Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.08
CY2020Q4	elcq	Warrants Issued WarrantsIssued	135000
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.50
CY2021Q1	elcq	Warrants Issued WarrantsIssued	2500000
CY2021Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.40
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3036792
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	684901
CY2021	elcq	Additional Interest Expense AdditionalInterestExpense	723166
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	29502
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	32068
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	33611
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	35371
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	37151
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	600000
CY2020Q2	us-gaap	Share Price SharePrice	0.30
CY2020Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	50000
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	535077
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	702780
CY2020Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10355
CY2020Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3759
CY2020Q4	us-gaap	Share Price SharePrice	1.33
CY2021Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1084120
CY2021Q1	elcq	Stock Issued During Period Value Conversion Of Convertible Note And Notes Payable StockIssuedDuringPeriodValueConversionOfConvertibleNoteAndNotesPayable	693837
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	831852
CY2021	elcq	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	1415685
CY2021	elcq	Derivative Liabilities In Conjunction With Promissory Notes DerivativeLiabilitiesInConjunctionWithPromissoryNotes	1197607
CY2021	elcq	Derivative Liabilities Conversion Of Notes Payable DerivativeLiabilitiesConversionOfNotesPayable	-3445144
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0
CY2020	elcq	Derivative Liabilities In Conjunction With Promissory Notes DerivativeLiabilitiesInConjunctionWithPromissoryNotes	903265
CY2020	elcq	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-71413
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	831852
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	158875
CY2022Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	57875
CY2021	elcq	Interest Income Expense Related Party Net InterestIncomeExpenseRelatedPartyNet	18590
CY2020	elcq	Interest Income Expense Related Party Net InterestIncomeExpenseRelatedPartyNet	386
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14585
CY2020Q1	us-gaap	Share Price SharePrice	0.71
CY2020Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	200000
CY2020Q1	elcq	Term Of Consulting Agreement TermOfConsultingAgreement	P12M
CY2020Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	102000
CY2020Q1	us-gaap	Share Price SharePrice	0.51
CY2020Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	900000
CY2020Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1818000
CY2021Q1	elcq	Stock Issued During Period Value Per Share Issued For Services StockIssuedDuringPeriodValuePerShareIssuedForServices	0.64
CY2021Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	50000
CY2020Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	142857
CY2020Q2	us-gaap	Share Price SharePrice	0.35
CY2020Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	35000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2020Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	26316
CY2020Q4	us-gaap	Share Price SharePrice	1.33
CY2020Q4	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	65000
CY2020Q4	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	55900
CY2020Q4	us-gaap	Share Price SharePrice	0.86
CY2020Q4	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	87849
CY2020Q4	us-gaap	Treasury Stock Value Acquired Par Value Method TreasuryStockValueAcquiredParValueMethod	36413
CY2020Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	5000
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	8400
CY2021Q2	elcq	Stock Issued During Period Value Per Share Issued For Services StockIssuedDuringPeriodValuePerShareIssuedForServices	0.168
CY2021Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1200000
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	102000
CY2021Q2	elcq	Stock Issued During Period Value Per Share Issued For Services StockIssuedDuringPeriodValuePerShareIssuedForServices	0.085
CY2021Q4	elcq	Common Stock Number Of Classes Of Stock CommonStockNumberOfClassesOfStock	2
CY2021Q4	elcq	Common Stock Number Of Shares Designated CommonStockNumberOfSharesDesignated	250000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	elcq	Stock Issued During Period Shares Issued For Debt Settlement StockIssuedDuringPeriodSharesIssuedForDebtSettlement	2000000
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	1699800
CY2020	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	118000
CY2021	elcq	Debt Conversion Converted Instrument Accrued Interest Amount DebtConversionConvertedInstrumentAccruedInterestAmount	49334051
CY2020	elcq	Debt Conversion Converted Instrument Accrued Interest Amount DebtConversionConvertedInstrumentAccruedInterestAmount	339429
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	2500000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21807
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	445000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.71
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y6M
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	445000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.71
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y6M
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	445000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.71
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y6M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	420000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.71
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P0Y6M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	445000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.71
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P0Y6M
CY2020Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	100000
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.52
CY2020Q2	elcq	Warrants Issued WarrantsIssued	250000
CY2020Q2	elcq	Warrants Issued WarrantsIssued	250000
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.00
CY2020Q2	elcq	Increase In Underlying Shares Warrants IncreaseInUnderlyingSharesWarrants	714286
CY2020Q2	elcq	Warrants Issued WarrantsIssued	250000
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.35
CY2020Q2	elcq	Reduction To Retained Earnings And Increase In Additional Paid In Capital ReductionToRetainedEarningsAndIncreaseInAdditionalPaidInCapital	371069
	elcq	Shares Issued On Warrant Cancellation SharesIssuedOnWarrantCancellation	1000000
CY2020Q4	elcq	Warrants Issued WarrantsIssued	135000
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	135000
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.50
CY2020Q4	elcq	Increase In Underlying Shares Warrants IncreaseInUnderlyingSharesWarrants	368182
CY2020Q4	elcq	Warrants Issued WarrantsIssued	135000
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.55
CY2020Q4	elcq	Reduction To Retained Earnings And Increase In Additional Paid In Capital ReductionToRetainedEarningsAndIncreaseInAdditionalPaidInCapital	136238
CY2021Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2500000
CY2021Q1	elcq	Warrants Issued WarrantsIssued	2500000
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.40
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.025
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	6249999
CY2021Q4	elcq	Warrants Issued WarrantsIssued	6249999
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.12
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.062
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	18468499
CY2021	elcq	Reduction To Retained Earnings And Increase In Additional Paid In Capital ReductionToRetainedEarningsAndIncreaseInAdditionalPaidInCapital	3770831

Files In Submission

Name	View Source	Status
0001410578-22-000752-index-headers.html	Edgar Link	pending
0001410578-22-000752-index.html	Edgar Link	pending
0001410578-22-000752.txt	Edgar Link	pending
0001410578-22-000752-xbrl.zip	Edgar Link	pending
elcq-20211231.xsd	Edgar Link	pending
elcq-20211231x10k.htm	Edgar Link	pending
elcq-20211231x10k001.jpg	Edgar Link	pending
elcq-20211231x10k_htm.xml	Edgar Link	completed
elcq-20211231xex10d17.htm	Edgar Link	pending
elcq-20211231xex10d24.htm	Edgar Link	pending
elcq-20211231xex10d24001.jpg	Edgar Link	pending
elcq-20211231xex10d24002.jpg	Edgar Link	pending
elcq-20211231xex10d25.htm	Edgar Link	pending
elcq-20211231xex10d25001.jpg	Edgar Link	pending
elcq-20211231xex10d26.htm	Edgar Link	pending
elcq-20211231xex10d27.htm	Edgar Link	pending
elcq-20211231xex10d28.htm	Edgar Link	pending
elcq-20211231xex10d29.htm	Edgar Link	pending
elcq-20211231xex10d30.htm	Edgar Link	pending
elcq-20211231xex10d31.htm	Edgar Link	pending
elcq-20211231xex10d32.htm	Edgar Link	pending
elcq-20211231xex31d1.htm	Edgar Link	pending
elcq-20211231xex31d2.htm	Edgar Link	pending
elcq-20211231xex32d1.htm	Edgar Link	pending
elcq-20211231_cal.xml	Edgar Link	unprocessable
elcq-20211231_def.xml	Edgar Link	unprocessable
elcq-20211231_lab.xml	Edgar Link	unprocessable
elcq-20211231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EMED
Electromedical Technologies, Inc Stock $emed

2021 Q4 Form 10-K Financial Statement

#000141057822000752 Filed on March 31, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMED Electromedical Technologies, Inc Stock $emed

2021 Q4 Form 10-K Financial Statement

#000141057822000752 Filed on March 31, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMED
Electromedical Technologies, Inc Stock $emed